Björn Larsson, CEO RLS Global, about the ongoing rights issue and market launch

Meet Björn Larsson, new CEO of RLS Global, when interviewed by Biostock about the ongoing rights issue and the market launch of ChloraSolv. Click to read the interview here.

News


Press Releases

Advanced Wound Care

Hard to heal wounds is a serious and costly complication of underlying diseases such as diabetes, venous insufficiency or injuries to the skin such as pressure ulcers. Patients suffering from these wounds often experience pain, bad smell, decreased mobility and other problems which seriously affecting the quality of life. Our overall goal is to provide a gentle and effective debridement method that result in improved wound care for healthcare professionals reducing the suffering for patients and the overall cost for the society in treating complicated wounds. Due to the unique buffered hypochlorite technology developed by RLS Global , ChloraSolv allows for a gentle debridement where devitalized tissue is removed while health tissue is preserved.

More about Advanced Wound Care

We support people to improve their health and Quality of LifeOur guiding principle is Patient Safety

At RLS Global, we are committed to creating sustainable value for all our stakeholders. Our mission is to develop products and procedures that help healthcare professionals to achieve improved treatment outcomes.

More about R&D